Law Firms Seek Skye Bioscience Investors to Lead Securities Class Action

Overview

• Notices from The Schall Law Firm, The Gross Law Firm, and Rosen Law Firm invite SKYE shareholders to participate in the case.
• The lawsuit alleges violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5.
• Plaintiffs claim Skye misrepresented the effectiveness of nimacimab and overstated its clinical, regulatory, and commercial prospects.
• The alleged class period spans November 4, 2024 through October 3, 2025.
• No class has been certified, and investors are not represented by counsel unless they retain one or a class is certified.